Advances in prevention and diagnosis of hepatocellular carcinoma (Q37345951)

19 August 2017

1 reference

title

Advances in prevention and diagnosis of hepatocellular carcinoma (English)

1 reference

19 August 2017

0 references

Hans Christian Spangenberg

series ordinal

1

1 reference

PubMed ID

19072390

19 August 2017

Robert Thimme

series ordinal

2

1 reference

PubMed ID

19072390

19 August 2017

Hubert E Blum

series ordinal

3

1 reference

19 August 2017

1 June 2008

1 reference

Expert Review of Gastroenterology & Hepatology

19 August 2017

1 reference

19 August 2017

2

1 reference

19 August 2017

3

1 reference

19 August 2017

425-433

1 reference

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

19 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Prognostic prediction and treatment strategy in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Hepatocellular carcinoma: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Chemoembolization for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Hepatocellular carcinoma: recent trends in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Hepatocellular carcinoma: recent trends in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Advancements in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Hepatitis B e antigen and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Environmental factors and risk for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Alcohol and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Obesity and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Coffee drinking and hepatocellular carcinoma risk: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Tumour suppressors in liver carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Genetic aspects of hepatocellular carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Liver pathology in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Telomeres and telomerase: a dual role in hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Immune pathogenesis of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

NF-kappaB functions as a tumour promoter in inflammation-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Diagnosis and staging of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Elevated plasma osteopontin levels in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

Hepatocellular Carcinoma: Trends of Incidence and Survival in Europe and the United States at the End of the 20th Century

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.3.425

21 January 2018

Identifiers

DOI

10.1586/17474124.2.3.425

1 reference

19 August 2017

1 reference

PubMed ID

19072390